CXF11

CXF11 is an inhaled tiotropium bromide product developed by Chance Pharmaceuticals for maintenance treatment of chronic obstructive pulmonary disease, specifically the prevention of bronchospasm in adults with COPD. Tiotropium bromide is a long-acting muscarinic antagonist small molecule bronchodilator that blocks airway muscarinic acetylcholine receptors, thereby reducing cholinergic bronchoconstriction and promoting sustained bronchodilation. Based on the provided context, CXF11 uses Chance Pharmaceuticals' proprietary inhaler device with improved usability and visual design relative to reference products, and its China marketing application was accepted after successful bioequivalence and stability studies, consistent with development of a tiotropium bromide generic or reference-comparable inhalation product.

Other names

tiotropium bromide inhalation drug